Every Form 4 that Hims & Hers Health, Inc. (HIMS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HIMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIMS filings page.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton sold 3,461 shares of Class A Common Stock on October 14, 2026, at $29.06 per share. The sale was made under a Rule 10b5-1 trading plan adopted on May 21, 2026. After the sale, Boughton directly held 297,348 shares.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe sold 2,000 shares of Class A Common Stock at $29.70 per share on October 1, 2026. The sale was made under a Rule 10b5-1 trading plan adopted on May 20, 2026. His reported direct holdings after the sale were 234,527 shares.
Hims & Hers Health, Inc. (HIMS) Chief Legal Officer Soleil Boughton sold 3,461 shares of Class A Common Stock at $29.17 per share on September 30, 2026, under a Rule 10b5-1 trading plan adopted on May 21, 2026. The transaction is described as a sale in the open market or a private transaction. Following the sale, Boughton directly held 300,809 shares.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised options for 14,000 Class A common shares at $5.01 per share and sold 29,277 shares at $29.95 per share on September 22, 2026. The option award was fully vested, and the exercise and sale were made under a Rule 10b5-1 trading plan adopted on May 20, 2026. After the exercise, he reported 66,872 options; 7,853 Class A common shares were held indirectly by the Oluyemi Okupe Separate Property Trust.
Hims & Hers Health, Inc. (HIMS) reported that its Chief Financial Officer, Oluyemi Okupe, sold 12,313 shares of Class A Common Stock on September 17, 2026 at $28.82 per share in an open-market transaction pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 20, 2026. Following this sale, he directly held 251,804 shares and indirectly held 7,853 shares through a separate property trust.
Hims & Hers Health, Inc. (HIMS) reported that its Chief Legal Officer, Soleil Boughton, sold 6,236 shares of Class A Common Stock on September 16, 2026 at $27.86 per share in an open market or private transaction. After this sale, the officer directly holds 304,270 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026.
Hims & Hers Health, Inc. (HIMS) reported that Chief Operating Officer Michael Chi sold Class A Common Stock in a routine insider transaction. On September 15, 2026, he sold 14,027 shares at $28.39 per share in an open market or private transaction under a Rule 10b5-1 trading plan adopted on December 1, 2025. After this sale, he continued to hold 456,660 shares of Class A Common Stock directly.
Hims & Hers Health, Inc. (HIMS) reports that its Chief Technology Officer, Mohamed Elshenawy, sold 7,954 shares of Class A Common Stock on September 15, 2026 in a sale characterized as an open market or private transaction at $28.39 per share. After this transaction, he directly holds 185,556 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 1, 2025 by the reporting person.
Hims & Hers Health, Inc. (HIMS) reported that Chief Legal Officer Soleil Boughton sold 3,458 shares of Class A Common Stock on September 2, 2026 at $28.33 per share in an open-market or private transaction. After this sale, Boughton directly holds 310,506 shares, and the sale was executed under a Rule 10b5-1 trading plan adopted on May 21, 2026.
Hims & Hers Health, Inc. (HIMS) reported that Chief Executive Officer and director Andrew Dudum made indirect transfers of Class A Common Stock tied to estate planning. On 2026-08-27, a trust associated with him completed a code J transaction distributing 977,566 shares pro rata to its beneficiaries for bona fide estate planning purposes, with no consideration received. On 2026-08-25, a trust associated with him made a code G bona fide gift of 463,289 shares, also for no consideration. Following these transactions, Dudum continues to hold shares both directly and indirectly through multiple trusts.
Hims & Hers Health, Inc. (HIMS) reported an insider transaction by director and Chief Policy Officer Deborah M. Autor. On August 18, 2026, she sold 16,773 shares of Class A Common Stock at $27.85 per share in an open-market or private transaction pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026, and now holds 48,961 shares directly.
Hims & Hers Health, Inc. (HIMS) reported that Chief Financial Officer Oluyemi Okupe exercised stock options for 4,938 shares of Class A Common Stock at an exercise price of $5.0100 per share and on the same date sold 4,938 shares at a weighted average price of $29.9942 per share. The option exercise and related sale were effected under a Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe held 80,872 stock options directly and 7,853 shares of Class A Common Stock indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. (HIMS) reported that Chief Legal Officer Soleil Boughton sold 25,111 shares of Class A Common Stock on August 19, 2026 at $27.55 per share. The sales were effected under a Rule 10b5-1 trading plan adopted on May 21, 2026, and Boughton now directly holds 313,964 shares.
Hims & Hers Health, Inc. (HIMS) reported equity compensation activity for Chief Legal Officer Soleil Boughton. On 2026-08-14, several tranches of Restricted Stock Units were converted into a total of 42,261 shares of Class A Common Stock at no cash exercise price. In connection with this RSU vesting and settlement, 21,500 shares were withheld by the issuer to satisfy tax withholding obligations at a price of $28.15 per share. The RSUs each represent the right to receive one share of Class A Common Stock and are subject to a 4-year service-based vesting schedule, vesting in substantially equal quarterly installments starting on different dates from June 15, 2023 through June 15, 2026.
Hims & Hers Health, Inc. (HIMS) director Kare Schultz reported the vesting and settlement of restricted stock units into Class A Common Stock. On 2026-08-14, 6,623 RSUs converted into 6,623 shares, increasing direct holdings to 26,020 shares. The RSUs were granted at no cash exercise price and, per the award terms, vest in three substantially equal installments over three years of continuous board service.
Hims & Hers Health, Inc. (HIMS) reported that Chief Medical Officer Patrick Harrison Carroll exercised and settled several Restricted Stock Unit (RSU) awards into a total of 26,187 shares of Class A Common Stock on 2026-08-14 at a conversion price of $0.00 per share. The company withheld 10,201 shares at $28.15 per share to cover tax withholding obligations related to these vestings. Footnotes state that one RSU grant was issued under the issuer’s Director Compensation Policy in lieu of $7,912 of cash fees at a grant price of $30.40, and that other RSU blocks vest over four years based on continued service.
Hims & Hers Health, Inc. (HIMS) reported insider equity activity by CEO and 10% owner Andrew Dudum on 2026-08-14. Several tranches of Restricted Stock Units (RSUs) were vested and converted into 154,993 shares of Class A Common Stock, reflecting equity compensation. Of these, 78,859 shares were withheld by the issuer at $28.15 per share to satisfy tax withholding obligations, rather than sold in the market. The RSU grants vest over four-year service-based schedules in substantially equal quarterly installments beginning on various dates from June 15, 2023 through June 15, 2026. Following these transactions, Dudum continues to hold substantial indirect Class A Common Stock positions through multiple family and GRAT trusts, with individual post-transaction balances reported for each trust.
Hims & Hers Health, Inc. (HIMS) reported that Chief Operating Officer Michael Chi had multiple restricted stock unit (RSU) awards vest on 2026-08-14, converting into 86,265 shares of Class A Common Stock at a price of $0.00 per share. In connection with this vesting and settlement, the company withheld 47,702 shares at a price of $28.15 per share to satisfy tax withholding obligations. The RSU grants vest over four years in substantially equal quarterly installments, with different grants beginning to vest on quarterly dates starting between December 15, 2022 and June 15, 2026.
Hims & Hers Health, Inc. (HIMS) reported that its Chief Financial Officer, Oluyemi Okupe, executed several equity transactions. On August 17, 2026, he exercised 9,388 stock options for Class A Common Stock at an exercise price of $5.01 per share, then sold 9,388 shares of Class A Common Stock at a weighted average price of $27.8869 per share pursuant to a Rule 10b5-1 trading plan. The underlying stock option award is fully vested, with 85,810 options reported as held directly after the exercise.
On August 14, 2026, multiple tranches of Restricted Stock Units (RSUs) vested and converted into an aggregate of 71,616 shares of Class A Common Stock, reflecting several service-based RSU awards that vest in substantially equal quarterly installments over four-year periods starting on June 15 of 2023, 2024, 2025, and 2026. In connection with this vesting, 36,437 shares of Class A Common Stock were withheld by the company at $28.15 per share to cover tax withholding obligations. Earlier, on June 18, 2026, Okupe sold 55,383 shares of Class A Common Stock at a weighted average price of $35.09 per share, also under the same Rule 10b5-1 trading plan.
Hims & Hers Health, Inc. (HIMS) reported that Chief Policy Officer and director Deborah M. Autor had 32,920 Restricted Stock Units (RSUs) vest and convert into an equal number of shares of Class A Common Stock on August 14, 2026. Of these, 16,147 shares were withheld by the company at $28.15 per share to cover tax withholding obligations. After this RSU exercise and related tax withholding, she reported direct holdings of 427,953 RSUs, which continue to vest quarterly over a four-year service-based schedule beginning March 15, 2026.
Hims & Hers Health, Inc. (HIMS) director David B. Wells reported equity compensation activity involving 778 Restricted Stock Units (RSUs) on August 14, 2026. Each RSU represents a contingent right to receive one share of Class A Common Stock, granted under the company’s Director Compensation Policy in lieu of a cash retainer. The filing notes that the RSUs, calculated from $23,760 of foregone cash fees at a $30.40 grant price, will vest in full on the company’s next quarterly vesting date. Following the reported transactions, Wells is shown with 229,808 shares of Class A Common Stock held directly.
Hims & Hers Health, Inc. reported equity compensation activity by CTO Mohamed Elshenawy involving the vesting and settlement of restricted stock units (RSUs) into Class A Common Stock. On 2026-08-14, RSUs covering 188,285 shares were exercised/converted into an equal number of Class A shares. In connection with this vesting, 95,798 shares of Class A Common Stock were withheld by the company at $28.15 per share to satisfy tax withholding obligations. The RSU awards are subject to service-based vesting over 3- and 4-year periods, with initial and subsequent vesting occurring on the company’s quarterly vesting dates beginning June 15, 2026.
Hims & Hers Health, Inc. (HIMS) reported that officer Irene Becklund (PAO) had Restricted Stock Units (RSUs) vest and convert into 13,685 shares of Class A Common Stock on 2026-08-14, pursuant to multi‑year, service-based, quarterly vesting schedules. In connection with this vesting, 6,490 shares of Class A Common Stock were withheld by the company at $28.15 per share to cover tax withholding obligations. The filing does not report updated post-transaction share holdings.
Hims & Hers Health, Inc. (HIMS) director Christopher D. Payne reported an exercise of 545 Restricted Stock Units (RSUs) into 545 shares of Class A common stock on 2026-08-14, leaving him with 34,863 shares held directly and 110,000 shares held indirectly through The Payne Family Trust. The RSUs represent a contingent right to receive one share of Class A common stock per unit and were issued under the company’s Director Compensation Policy in lieu of the second-quarter 2026 cash retainer fee, with the $16,598 foregone fees divided by a $30.40 grant price to determine the grant amount; the RSUs will vest in full on the company’s next quarterly vesting date.
Elshenawy Mohamed reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that CTO Mohamed Elshenawy received a grant of 1,200,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A Common Stock. The RSUs carry a service-based vesting requirement over 3 years, vesting in substantially equal quarterly installments starting on the first company quarterly vesting date following the grant. Following this award, Elshenawy holds 1,200,000 RSUs directly.
Schultz Kare reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that director Schultz Kare received a grant of 8,223 Restricted Stock Units (RSUs), each representing a right to receive one share of Class A Common Stock. Subject to continuous service, these RSUs will vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date.
Payne Christopher D reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Christopher D. Payne reported two equity compensation awards in the form of Restricted Stock Units (RSUs) linked to Class A Common Stock. He received 8,223 RSUs that, subject to continuous service, will vest on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date. He also received 545 RSUs issued under the Director Compensation Policy in lieu of a second-quarter 2026 cash retainer, calculated by dividing $16,598 of foregone fees by a $30.40 grant price; these RSUs will vest on the company’s next quarterly vesting date.
Perez Garcia Andrea G reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Andrea G Perez Garcia received a grant of 8,223 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A Common Stock. Subject to continuous service, the RSUs will vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date. Following this award, reported direct holdings from this grant total 8,223 shares underlying RSUs.
Manuel Anja reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Manuel Anja received a grant of 8,223 Restricted Stock Units (RSUs) on August 12, 2026. Each RSU represents a contingent right to receive one share of Class A common stock. Subject to continuous service, all RSUs will vest on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date, resulting in 8,223 shares held directly after the grant.
Cosgrove Delos M. reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director Delos M. Cosgrove reported an award of 8,223 Restricted Stock Units (RSUs) relating to Class A Common Stock. The RSUs were granted at $0.00 per unit, bringing his reported direct holdings from this award to 8,223 RSUs.
Each RSU represents a contingent right to receive one share of Class A Common Stock. Subject to continuous service, the RSUs will vest in full on the first quarterly vesting date after the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date.
Autor Deborah M. reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Policy Officer and director Deborah M. Autor received a grant of 8,223 Restricted Stock Units (RSUs) on 2026-08-12. Each RSU represents a contingent right to receive one share of Class A Common Stock, leaving her with 8,223 RSUs directly held after the award.
Subject to continuous service, these RSUs will vest in full on the first company quarterly vesting date following the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date.
Carroll Patrick Harrison reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that Chief Medical Officer Patrick Harrison Carroll received a grant of 260 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock. The award was issued under the company’s Director Compensation Policy in lieu of a second-quarter 2026 director retainer fee of $7,912, based on a grant price of $30.40 per share. The RSUs will vest in full on the company’s next quarterly vesting date, after which the underlying shares may be delivered.
WELLS DAVID B reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. director David B. Wells reported two equity compensation awards in the form of Restricted Stock Units (RSUs). He received 8,223 RSUs, each representing one share of Class A common stock, which will vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date, subject to continuous service. He also received 778 RSUs issued under the Director Compensation Policy in lieu of a $23,760 cash retainer for the second quarter of 2026, calculated at a grant price of $30.40 per share and vesting on the company’s next quarterly vesting date.
Amoo-Gottfried Kofi Owusu reported acquisition or exercise transactions in this Form 4 filing.
Hims & Hers Health, Inc. reported that director Kofi Owusu Amoo-Gottfried received two equity compensation awards of Restricted Stock Units (RSUs) on August 12, 2026. One award covers 13,157 RSUs that, subject to continuous service, vest in three substantially equal installments over three years on company quarterly vesting dates. A second award covers 8,223 RSUs that, subject to continuous service, vest in full on the first quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date.
Hims & Hers Health CFO Oluyemi Okupe exercised stock options for 7,163 Class A shares at $5.0100 on July 17, 2026, then sold 7,163 shares at a weighted-average price of $31.9933 under a Rule 10b5-1 plan adopted May 21, 2025. After these transactions he holds 284,321 Class A shares directly, 7,853 shares indirectly through a separate property trust, and 95,198 stock options remaining.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an option exercise and related share sale in Class A Common Stock. Okupe exercised stock options to acquire 7,163 shares at a price of $5.0100 per share, then sold 7,163 shares at an average price of $36.4863 per share.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe holds 284,321 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021, along with 102,361 stock options remaining outstanding.
Hims & Hers Health, Inc. Chief Medical Officer Patrick Harrison reported an open-market sale of Class A Common Stock. He sold 23,726 shares at a price of $35.00 per share. After this transaction, he directly holds 181,861 shares of the company’s Class A Common Stock.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported an exercise of stock options and a sale of common shares. He exercised 6,376 shares of Class A common stock at $5.01 per share and sold 18,197 shares at an average price of $34.0285 per share. The filing states these option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following the transactions, Okupe directly holds 284,321 shares of Class A common stock and indirectly holds 7,853 shares through the Oluyemi Okupe Separate Property Trust.
Hims & Hers Health Chief Medical Officer Patrick Harrison reported routine equity compensation activity. On June 15, 2026, he acquired 25,926 shares of Class A Common Stock through the vesting and settlement of Restricted Stock Units (RSUs). To cover related tax withholding obligations, 8,310 shares were withheld by the company rather than sold on the open market.
Following these transactions, Harrison directly held 205,587 shares of Class A Common Stock. The RSUs vest under multi‑year, service-based schedules, with portions vesting on company quarterly vesting dates through future years.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported compensation-related equity activity involving Class A Common Stock and Restricted Stock Units (RSUs). On June 15, 2026, RSUs were exercised to deliver 71,616 shares of Class A Common Stock, reflecting vesting under prior equity awards. To cover associated tax withholding obligations, 39,541 shares of Class A Common Stock were withheld by the company at $30.17 per share, rather than sold on the open market. Following these transactions, Okupe directly held 296,142 shares of Class A Common Stock and indirectly held 7,853 shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The footnotes explain that each RSU converts into one share of Class A Common Stock and that the RSUs vest in substantially equal quarterly installments over four years, with first vesting dates ranging from June 15, 2023 to June 15, 2026.
Hims & Hers Health, Inc. Chief Policy Officer Deborah M. Autor reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, 32,919 RSUs converted into an equal number of Class A Common shares. Of these, 15,396 shares were withheld at a price of $30.17 per share to cover tax obligations, leaving her with 48,961 Class A Common shares held directly after the transactions. Following the RSU conversion, she also held 460,873 RSUs, which carry a service-based vesting schedule over four years, vesting in substantially equal quarterly installments beginning on March 15, 2026.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported multiple equity transactions involving Class A Common Stock and Restricted Stock Units. He exercised awards covering 86,264 shares of common stock on June 15, 2026, converting RSUs into shares at a stated price of $0.00 per share.
To cover tax obligations from these vestings, 47,699 shares of Class A Common Stock were withheld by the company at $30.17 per share. On June 17, 2026, he executed an open-market sale of 14,027 shares at $31.50 per share under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Chi directly owns 432,124 shares of Class A Common Stock. The RSUs are subject to four-year, service-based vesting in substantially equal quarterly installments under the company’s standard vesting schedules.
Hims & Hers Health, Inc. Principal Accounting Officer Irene Becklund reported a series of stock transactions tied to equity compensation. On June 15, 2026, she exercised awards and acquired 15,971 shares of Class A Common Stock as Restricted Stock Units vested.
Of these, 5,870 shares were withheld by the company to cover tax obligations related to the RSU vesting. She then sold 7,573 shares at $30.25 per share on June 16, 2026 and 4,490 shares at $31.50 per share on June 17, 2026, with both sales executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 6,790 shares of Class A Common Stock.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton reported routine equity compensation activity linked to restricted stock units (RSUs). On June 15, 2026, RSUs converted into 42,261 shares of Class A Common Stock, while 23,315 shares were withheld by the company to cover tax obligations. After these transactions, Boughton held 318,314 Class A shares directly, reflecting continued equity ownership rather than an open-market sale.
Hims & Hers Health Chief Executive Officer Andrew Dudum reported routine equity compensation activity involving Restricted Stock Units (RSUs). On June 15, 2026, he exercised RSUs covering 154,991 shares of Class A Common Stock at a conversion price of $0.00 per share.
To satisfy tax obligations tied to this vesting and settlement, 85,632 shares of Class A Common Stock were withheld by the company at $30.17 per share. Following these transactions, Dudum directly held 957,043 shares of Class A Common Stock and maintained additional indirect holdings through various family trusts, including 3,004,071 shares held by the Trustee of the Dudum Family 2021 Trust.
Hims & Hers Health, Inc. CTO Mohamed Elshenawy reported multiple equity transactions. He exercised derivative awards into 282,597 shares of Class A Common Stock on June 15, 2026, alongside RSU conversions totaling 282,597 underlying shares. On the same date, 151,534 shares were withheld by the company to cover tax obligations from RSU vesting. On June 17, 2026, he made an open-market sale of 30,040 shares at $31.50 per share under a pre-arranged Rule 10b5-1 trading plan, leaving him with 101,023 shares of Class A Common Stock held directly.
Hims & Hers Health director David B. Wells exercised stock units granted as board compensation and received additional common shares. On June 11, 2026 he converted 3,656 Restricted Stock Units into Class A Common Stock, and on June 15, 2026 he converted another 957 units, for a total of 4,613 shares. These RSUs were issued under the company’s Director Compensation Policy in lieu of $22,000 of cash fees, based on a grant price of $22.98 per unit. After these routine compensation-related transactions, Wells directly holds 229,030 shares of Class A Common Stock.
Hims & Hers Health director Kare Schultz exercised restricted stock units to acquire additional shares of Class A common stock. On June 11, 2026, 3,656 RSUs were converted into 3,656 shares of Class A common stock at a stated price of $0.00 per share. After this derivative exercise, Schultz directly owns 19,397 shares of Class A common stock. The RSUs represent a contingent right to receive one share of Class A common stock for each unit, subject to continuous service and vesting on the earlier of the 2026 annual meeting of stockholders or June 15, 2026.
Hims & Hers Health director Andrea G Perez Garcia exercised restricted stock units into common shares. On June 11, 2026, 3,656 Restricted Stock Units were converted into 3,656 shares of Class A Common Stock at a per-share price of $0.00.
Following this compensation-related transaction, Perez Garcia held 83,822 shares of Class A Common Stock directly. The footnote explains that the RSUs represent a right to receive one Class A share per unit and, subject to continuous service, will vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026.
Hims & Hers Health Chief Medical Officer Patrick Harrison reported routine equity compensation activity. On June 11 and June 15, 2026, he exercised Restricted Stock Units (RSUs) to acquire a total of 4,091 shares of Class A Common Stock at a conversion price of $0.00 per share, with the corresponding RSU derivative positions reduced to zero.
Following these transactions, Harrison directly owned 187,971 shares of Class A Common Stock, which includes 1,440 shares acquired on May 20, 2026 under the company’s 2020 Employee Stock Purchase Plan. Footnotes explain that RSUs represent the right to receive one share of Class A Common Stock for each unit and that a prior RSU grant was calculated by dividing foregone cash fees of $10,000 by a grant price of $22.98.